Use of Platelet Glycoprotein IIb/IIIa Inhibitors in Saphenous Vein Graft Percutaneous Coronary Intervention and Clinical Outcomes

American Journal of Cardiology

Volumn 98, Issue 7, 2006, Pages 906-910

  Karha, Juhana ^a   Gurm, Hitinder S ^a   Rajagopal, Vivek ^a   Fathi, Robert ^a   Bavry, Anthony A ^a   Brener, Sorin J ^a   Lincoff, A Michael ^a   Ellis, Stephen G ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE MB; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEVICE; EMBOLISM; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HEMATOMA; HUMAN; INCIDENCE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; Q WAVE; RETROPERITONEAL HEMORRHAGE; RETROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; SURVIVAL; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; EMBOLISM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MYOCARDIUM; NECROSIS; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; SAPHENOUS VEIN; SURVIVAL ANALYSIS;

EID: 33748748802     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.04.037     Document Type: Article

References (20)

1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 330 (1994) 956-961
2. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352 (1998) 87-92
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336 (1997) 1689-1696
4. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349 (1997) 1429-1435
5. Brener S.J., Barr L.A., Burchenal J.E., Katz S., George B.S., Jones A.A., Cohen E.D., Gainey P.C., White H.J., Cheek H.B., et al., ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98 (1998) 734-741
6. Stone G.W., Grines C.L., Cox D.A., Garcia E., and Tcheng J.E. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
7. Antoniucci D., Rodriguez A., Hempel A., Valenti R., Migliorini A., Vigo F., Parodi G., Fernandez-Pereira C., Moschi G., Bartorelli A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42 (2003) 1879-1885
8. Montalescot G., Barragan P., Wittenberg O., Ecollan P., and Elhadad S. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
9. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Lancet 356 (2000) 2037-2044
10. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 96 (1997) 1445-1453
11. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349 (1997) 1422-1428
12. Bhatt D.L., and Topol E.J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 284 (2000) 1549-1558
13. Bhatt D.L., and Topol E.J. Percutaneous coronary intervention for patients with prior bypass surgery: therapy in evolution. Am J Med 108 (2000) 176-177
14. Roffi M., Mukherjee D., Chew D.P., Bhatt D.L., Cho L., Robbins M.A., Ziada K.M., Brennan D.M., Ellis S.G., and Topol E.J. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation 106 (2002) 3063-3067
15. Mathew V., Grill D.E., Scott C.G., Grantham J.A., Ting H.H., Garratt K.N., and Holmes Jr. D.R. The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. J Am Coll Cardiol 34 (1999) 1163-1169
16. Curb J.D., Ford C.E., Pressel S., Palmer M., Babcock C., and Hawkins C.M. Ascertainment of vital status through the National Death Index and the Social Security Administration. Am J Epidemiol 121 (1985) 754-766
17. Baim D.S., Wahr D., George B., Leon M.B., Greenberg J., Cutlip D.E., Kaya U., Popma J.J., Ho K.K., and Kuntz R.E. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 105 (2002) 1285-1290
18. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339 (1998) 436-443
19. Jonas M., Stone G.W., Mehran R., Hermiller J., Feldman R., Herrmann H.C., Cox D.A., Kuntz R.E., Popma J.J., and Rogers C. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J 27 (2006) 920-928
20. Lincoff A.M., Califf R.M., and Topol E.J. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 35 (2000) 1103-1115